These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 6223579)

  • 1. Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice.
    Nakamura S; Nakata K; Katae H; Minami A; Kashimoto S; Yamagishi J; Takase Y; Shimizu M
    Antimicrob Agents Chemother; 1983 May; 23(5):742-9. PubMed ID: 6223579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections.
    Hirai K; Ito A; Abe Y; Suzue S; Irikura T; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1981 Jan; 19(1):188-9. PubMed ID: 6454381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo antibacterial activity of AT-2266.
    Kouno K; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1983 Jul; 24(1):78-84. PubMed ID: 6226242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pipemidic acid: its activities against various experimental infections.
    Shimizu M; Takdase Y; Nakamura S; Katae H; Minami A
    Antimicrob Agents Chemother; 1976 Apr; 9(4):569-74. PubMed ID: 1267435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH
    Chemotherapy; 1985; 31(1):34-9. PubMed ID: 3156026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antibacterial activity of norfloxacin and pipemidic acid in a randomized double-blind study].
    Zerqueni G; Rocca Rossetti S
    Minerva Urol Nefrol; 1984; 36(3):247-51. PubMed ID: 6241966
    [No Abstract]   [Full Text] [Related]  

  • 7. Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
    Teoh-Chan CH; Cowlishaw A; Eley A; Slater G; Greenwood D
    J Antimicrob Chemother; 1985 Jan; 15(1):45-52. PubMed ID: 3156113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
    Infection; 1985; 13(5):219-24. PubMed ID: 2933340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical uses of nalidixic acid analogues: the fluoroquinolones.
    Høiby N
    Eur J Clin Microbiol; 1986 Apr; 5(2):138-40. PubMed ID: 3013628
    [No Abstract]   [Full Text] [Related]  

  • 10. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A; Ullmann U
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():33-8. PubMed ID: 6238931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ethylenediaminetetraacetic acid and gentamicin on the antibacterial activity of pyridone carboxylic acid derivatives against gram-negative bacilli.
    Miyake Y; Mitsui K; Suginaka H
    J Antimicrob Chemother; 1986 Mar; 17(3):327-32. PubMed ID: 3084441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
    Obana Y; Nishino T
    Drugs Exp Clin Res; 1989; 15(2):53-8. PubMed ID: 2661182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antibacterial activity of AM-715, a new nalidixic acid analog.
    Ito A; Hirai K; Inoue M; Koga H; Suzue S; Irikura T; Mitsuhashi S
    Antimicrob Agents Chemother; 1980 Feb; 17(2):103-8. PubMed ID: 6446258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys.
    Nakamura S; Kurobe N; Kashimoto S; Ohue T; Takase Y; Shimizu M
    Antimicrob Agents Chemother; 1983 Jul; 24(1):54-60. PubMed ID: 6226241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues.
    Seibert G; Limbert M; Klesel N
    Eur J Clin Microbiol; 1983 Dec; 2(6):548-53. PubMed ID: 6230226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients.
    Panichi G; Pantosti A; Testore GP
    J Antimicrob Chemother; 1983 Jun; 11(6):589-92. PubMed ID: 6224769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo activity of NY-198, a new difluorinated quinolone.
    Hirose T; Okezaki E; Kato H; Ito Y; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1987 Jun; 31(6):854-9. PubMed ID: 3476021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
    Nakamura S; Minami A; Nakata K; Kurobe N; Kouno K; Sakaguchi Y; Kashimoto S; Yoshida H; Kojima T; Ohue T
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1167-73. PubMed ID: 2802544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraphagocytic bactericidal activity of bacterial DNA gyrase inhibitors against Serratia marcescens.
    Traub WH
    Chemotherapy; 1984; 30(6):379-86. PubMed ID: 6097410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.